Glioblastoma

Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma

Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma

By

EGFR-amplified tumors had a high rate of response.

Glioblastoma: Temozolomide, Bevacizumab May Improve Outcomes Among Elderly Patients

Glioblastoma: Temozolomide, Bevacizumab May Improve Outcomes Among Elderly Patients

By

Researchers enrolled 66 patients with glioblastoma to evaluate the safety and efficacy of upfront temozolomide with bevacizumab.

Tumor-treating Fields Do Not Negatively Affect Health-related QoL

Tumor-treating Fields Do Not Negatively Affect Health-related QoL

By

A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.

Sorafenib Plus Temsirolimus Demonstrates Limited Benefit in Glioblastoma

Sorafenib Plus Temsirolimus Demonstrates Limited Benefit in Glioblastoma

By

Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.

Tumor-treating Fields Improve Glioblastoma Outcomes

Tumor-treating Fields Improve Glioblastoma Outcomes

By

Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.

Tumor Treating Fields May Improve Glioblastoma Outcomes

Tumor Treating Fields May Improve Glioblastoma Outcomes

By

TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

By

First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.

Rindopepimut Not Associated With Prolonged Survival in Glioblastoma

Rindopepimut Not Associated With Prolonged Survival in Glioblastoma

By

At the preplanned interim analysis, the study was discontinued for futility.

Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype

Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype

By

Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.

FDA Grants Orphan Drug Status to SurVaxM for Glioblastoma

FDA Grants Orphan Drug Status to SurVaxM for Glioblastoma

By

The US Food and Drug Administration granted orphan drug status to SurVaxM for patients with glioblastoma.

Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma

Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma

By

Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.

Glioblastoma Survival Rates May Improve With New Immunotherapeutic Approach

Glioblastoma Survival Rates May Improve With New Immunotherapeutic Approach

By

New immunotherapeutic approaches, such as dendritic cell vaccination, may be effective for treating this rare brain cancer, which is associated with dismal survival rates.

Phase 3 Trial: Vaccine Trial for Patients with Glioblastoma

Phase 3 Trial: Vaccine Trial for Patients with Glioblastoma

By

Researchers are attempting to determine the clinical efficacy of ICT-107, a dendritic cell vaccine, among patients with newly diagnosed glioblastoma.

Can Height Increase the Risk of Glioblastoma?

Can Height Increase the Risk of Glioblastoma?

By

Height, but not body mass index, may be associated with risk of glioblastoma multiforme, the most aggressive form of brain cancer, and other glioma subtypes.

TTFields Prolong Overall Survival in Glioblastoma

TTFields Prolong Overall Survival in Glioblastoma

By

Adding Tumor Treating Fields (TTFields) to maintenance temozolomide significantly prolongs both median and long-term survival.

Onartuzumab Does Not Improve Clinical Outcomes in Glioblastoma

Onartuzumab Does Not Improve Clinical Outcomes in Glioblastoma

By

Onartuzumab does not improve clinical outcomes for patients with glioblastoma when given with bevacizumab.

Brain Cancer Treatment Regimens

Brain Cancer Treatment Regimens

View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.

FDA Approves Second Generation Optune System for Glioblastoma Treatment

FDA Approves Second Generation Optune System for Glioblastoma Treatment

By

The U.S. Food and Drug Administration (FDA) approved Novocure's premarket approval (PMA) supplement application for the second generation Optune System, which is intended for the treatment of glioblastoma.

New Technique May Help Predict Outcomes for Patients With Glioblastoma Multiforme

New Technique May Help Predict Outcomes for Patients With Glioblastoma Multiforme

By

Researchers have developed a new method to quantitatively screen cell migration responses of glioma cells to platelet-derived growth factor (PDGF).

BRCA1 Gene Expression May be Biomarker for Survival in Glioblastoma Multiforme

BRCA1 Gene Expression May be Biomarker for Survival in Glioblastoma Multiforme

By

BRCA1 protein expression may be an important predictive biomarker of overall survival in glioblastoma multiforme (GBM).

FDA Expands Indication for Optune Device for Newly Diagnosed Glioblastoma

FDA Expands Indication for Optune Device for Newly Diagnosed Glioblastoma

By

The FDA has approved expanded indication for the Optune device to treat patients with newly diagnosed glioblastoma multiforme.

1-Week Radiotherapy May Be Feasible for Elderly Patients with Newly Diagnosed Glioblastoma

1-Week Radiotherapy May Be Feasible for Elderly Patients with Newly Diagnosed Glioblastoma

By

No differences in overall survival time and quality of life in elderly and/or frail patients with newly diagnosed glioblastoma multiforme.

Bevacizumab May Add Survival Benefit for Wild-type Proneural Glioblastoma

Bevacizumab May Add Survival Benefit for Wild-type Proneural Glioblastoma

By

A retrospective analysis showed that first-line bevacizumab treatment may provide overall survival in glioblastoma.

Proton Therapy Well-Tolerated for Low-Grade Gliomas

Proton Therapy Well-Tolerated for Low-Grade Gliomas

Patients with low-grade glioma were found to tolerate proton radiation therapy without difficultly.

Bevacizumab-Induced Hypertension Indicative of Better Survival in Glioblastoma

Bevacizumab-Induced Hypertension Indicative of Better Survival in Glioblastoma

Glioblastoma patients who developed bevacizumab-induced hypertension experienced increased survival.

Study Classifies Gliomas Based on Tumor Markers

Study Classifies Gliomas Based on Tumor Markers

By

Gliomas classified by tumor markers were characterized by distinct mechanisms of pathogenesis, ages at onset and overall survival.

Tumor Treating Fields Improve Survival in Newly Diagnosed Glioblastoma

Tumor Treating Fields Improve Survival in Newly Diagnosed Glioblastoma

By

Tumor Treating Fields improved progression-free survival and overall survival in patients with newly diagnosed glioblastoma.

Efficacy of Chemotherapy Similar to Radiotherapy for Anaplastic Glioma

Efficacy of Chemotherapy Similar to Radiotherapy for Anaplastic Glioma

By

Long-term data do not support efficacy of primary temozolomide monotherapy versus radiotherapy in anapestic glioma.

Temozolomide with Radiotherapy Safer, Equally Effective as Nitrosureas for Anaplastic Astrocytoma

Temozolomide with Radiotherapy Safer, Equally Effective as Nitrosureas for Anaplastic Astrocytoma

By

Radiotherapy plus temozolomide did not appear to significantly improve survival for anapestic astrocytoma compared with nitrosurea.

Nivolumab Plus Ipilimumab Demonstrates Activity in Recurrent Glioblastoma

Nivolumab Plus Ipilimumab Demonstrates Activity in Recurrent Glioblastoma

By

The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs